董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Richard J. Barry | 男 | Independent Director | 66 | 21.77万美元 | 未持股 | 2025-08-12 |
| Claude Nicaise | 男 | Independent Director | 72 | 21.31万美元 | 未持股 | 2025-08-12 |
| Douglas Ingram | -- | Director,Chief Executive Officer | -- | 未披露 | 未持股 | 2025-08-12 |
| Deirdre P. Connelly | -- | Independent Director | -- | 未披露 | 未持股 | 2025-08-12 |
| Michael A. Chambers | -- | Independent Director | -- | 未披露 | 未持股 | 2025-08-12 |
| Stephen L. Mayo | -- | Independent Director | -- | 未披露 | 未持股 | 2025-08-12 |
| Kathryn Jean Boor | -- | Independent Director | -- | 未披露 | 未持股 | 2025-08-12 |
| M. Kathleen Behrens | 女 | Chairwoman of the Board | 72 | 27.10万美元 | 未持股 | 2025-08-12 |
| Hans Wigzell | 男 | Independent Director | 86 | 7.12万美元 | 未持股 | 2025-08-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ian Estepan | 男 | President and Chief Operating Officer | -- | 未披露 | 未持股 | 2025-08-12 |
| Louise Rodino Klapac | 女 | President, Research and Development and Technical Operations | -- | 未披露 | 未持股 | 2025-08-12 |
| Ryan Wong | 男 | Executive Vice President, Chief Financial Officer,Principal Accounting Officer | 46 | 未披露 | 未持股 | 2025-08-12 |
| Douglas Ingram | -- | Director,Chief Executive Officer | -- | 未披露 | 未持股 | 2025-08-12 |
| Cristin Rothfuss | -- | Executive Vice President, Chief General Counsel and Corporate Secretary | -- | 未披露 | 未持股 | 2025-08-12 |
董事简历
中英对照 | 中文 | 英文- Richard J. Barry
-
Richard J. Barry，自2015年6月起担任董事会成员。他还担任审计委员会成员以及提名和公司治理委员会成员和主席。巴里先生是该公司的长期股东。他自2013年2月起担任制药公司Elcelyx Therapeutics的董事，并且是GSM Fund，LLC的管理成员，该基金成立的唯一目的是投资Elcelyx。自2009年以来，Barry先生还一直是圣地亚哥教士队的合伙人和顾问委员会成员，自2014年以来一直是宾夕法尼亚州立大学Schreyer荣誉学院的顾问委员会成员。此前，他曾担任位于圣地亚哥的软件公司Cluster Wireless和能源研究公司Blacklight Power的董事。Barry先生在投资管理业务方面拥有丰富的经验。他是伊斯特本资本管理有限责任公司的创始成员，伊斯特本资本管理有限责任公司是一家投资于包括医疗保健在内的多种行业的大型股票对冲基金，并在1999年至2010年结束期间担任管理普通合伙人和投资组合经理。在加入伊斯特本之前，Barry先生是Robertson Stephens Investment Management的投资组合经理和董事总经理。Barry先生还在机构股权和投资管理公司担任过超过13年的职务，包括Lazard Freres、美盛集团和美林证券。Barry先生拥有宾夕法尼亚州立大学的学士学位。
Richard J. Barry, has served as a member of Board since June 2015. He also serves as a member of audit committee and as a member and chairperson of nominating and corporate governance committee. Mr. Barry is a long time stockholder of the Company. He has served as a director for Elcelyx Therapeutics, a pharmaceutical company, since February 2013 and is a Managing Member of GSM Fund, LLC, a fund established for the sole purpose of investing in Elcelyx. Mr. Barry has also been a Partner and Advisory Board member of the San Diego Padres since 2009 and an Advisory Board member for the Schreyer Honors College at Pennsylvania State University since 2014. He previously served as a director of Cluster Wireless, a San Diego-based software company, and Blacklight Power, an energy research company. Mr. Barry has extensive experience in the investment management business. He was a founding member of Eastbourne Capital Management LLC, a large equity hedge fund investing in a variety of industries, including health care, and served as a Managing General Partner and Portfolio Manager from 1999 to its close in 2010. Prior to Eastbourne, Mr. Barry was a Portfolio Manager and Managing Director of Robertson Stephens Investment Management. Mr. Barry also spent over 13 years in various roles in institutional equity and investment management firms, including Lazard Freres, Legg Mason and Merrill Lynch. Mr. Barry holds a B.A. from Pennsylvania State University. - Richard J. Barry，自2015年6月起担任董事会成员。他还担任审计委员会成员以及提名和公司治理委员会成员和主席。巴里先生是该公司的长期股东。他自2013年2月起担任制药公司Elcelyx Therapeutics的董事，并且是GSM Fund，LLC的管理成员，该基金成立的唯一目的是投资Elcelyx。自2009年以来，Barry先生还一直是圣地亚哥教士队的合伙人和顾问委员会成员，自2014年以来一直是宾夕法尼亚州立大学Schreyer荣誉学院的顾问委员会成员。此前，他曾担任位于圣地亚哥的软件公司Cluster Wireless和能源研究公司Blacklight Power的董事。Barry先生在投资管理业务方面拥有丰富的经验。他是伊斯特本资本管理有限责任公司的创始成员，伊斯特本资本管理有限责任公司是一家投资于包括医疗保健在内的多种行业的大型股票对冲基金，并在1999年至2010年结束期间担任管理普通合伙人和投资组合经理。在加入伊斯特本之前，Barry先生是Robertson Stephens Investment Management的投资组合经理和董事总经理。Barry先生还在机构股权和投资管理公司担任过超过13年的职务，包括Lazard Freres、美盛集团和美林证券。Barry先生拥有宾夕法尼亚州立大学的学士学位。
- Richard J. Barry, has served as a member of Board since June 2015. He also serves as a member of audit committee and as a member and chairperson of nominating and corporate governance committee. Mr. Barry is a long time stockholder of the Company. He has served as a director for Elcelyx Therapeutics, a pharmaceutical company, since February 2013 and is a Managing Member of GSM Fund, LLC, a fund established for the sole purpose of investing in Elcelyx. Mr. Barry has also been a Partner and Advisory Board member of the San Diego Padres since 2009 and an Advisory Board member for the Schreyer Honors College at Pennsylvania State University since 2014. He previously served as a director of Cluster Wireless, a San Diego-based software company, and Blacklight Power, an energy research company. Mr. Barry has extensive experience in the investment management business. He was a founding member of Eastbourne Capital Management LLC, a large equity hedge fund investing in a variety of industries, including health care, and served as a Managing General Partner and Portfolio Manager from 1999 to its close in 2010. Prior to Eastbourne, Mr. Barry was a Portfolio Manager and Managing Director of Robertson Stephens Investment Management. Mr. Barry also spent over 13 years in various roles in institutional equity and investment management firms, including Lazard Freres, Legg Mason and Merrill Lynch. Mr. Barry holds a B.A. from Pennsylvania State University.
- Claude Nicaise
-
Claude Nicaise，自2021年3月16日起担任董事会成员。Nicaise博士是一名医生，在临床药物开发、战略管理、全球监管战略、制药、生物技术，包括临床癌症研究、传染病和神经科学方面拥有丰富的美国和国际经验。Nicaise博士是Clinical Regulatory Services的所有者和创始人，Clinical Regulatory Services为生命科学和生物技术行业提供咨询服务，以支持临床和监管发展的各个方面。Nicaise博士目前担任Sarepta Therapeutics, Inc.的董事会成员和薪酬委员会主席，自2015年起担任Sarepta Therapeutics, Inc.董事，并自2017年起担任Mynoryx Therapeutics的董事会成员。在此之前，2008年至2014年，Nicaise博士担任亚力兄制药 Inc.（纳斯达克股票代码：ALXN）的高级副总裁，1984年至2008年期间，他在百时美施贵宝（纽约证券交易所股票代码：BMY）担任过多个高级管理职务。Nicaise博士拥有比利时布鲁塞尔大学的医学博士和内科、临床肿瘤学学位。
Claude Nicaise has served on board of directors since March 16 2021. Dr. Nicaise is a physician with extensive US and international experience in clinical drug development, strategic management, worldwide regulatory strategy, pharmaceuticals, biotechnology, including clinical cancer research, infectious diseases and neuroscience. Dr. Nicaise is the owner and founder of Clinical Regulatory Services, which provides consulting services to the life science and biotechnology industry in support of all aspects of clinical and regulatory development. Dr. Nicaise currently serves on the board of directors and as the Chairman of the Compensation Committee of Sarepta Therapeutics, Inc. NASDAQ: SRPT, since 2015 as well as on the board of directors of Mynoryx Therapeutics, since 2017. Prior to that time, from 2008 to 2014 Dr. Nicaise served as the Senior Vice President of Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), and between 1984 and 2008 he held numerous senior management roles at Bristol Myers Squibb (NYSE: BMY). Dr. Nicaise holds an MD and a degree in Internal Medicine, Clinical Oncology, from Brussels University, Belgium. - Claude Nicaise，自2021年3月16日起担任董事会成员。Nicaise博士是一名医生，在临床药物开发、战略管理、全球监管战略、制药、生物技术，包括临床癌症研究、传染病和神经科学方面拥有丰富的美国和国际经验。Nicaise博士是Clinical Regulatory Services的所有者和创始人，Clinical Regulatory Services为生命科学和生物技术行业提供咨询服务，以支持临床和监管发展的各个方面。Nicaise博士目前担任Sarepta Therapeutics, Inc.的董事会成员和薪酬委员会主席，自2015年起担任Sarepta Therapeutics, Inc.董事，并自2017年起担任Mynoryx Therapeutics的董事会成员。在此之前，2008年至2014年，Nicaise博士担任亚力兄制药 Inc.（纳斯达克股票代码：ALXN）的高级副总裁，1984年至2008年期间，他在百时美施贵宝（纽约证券交易所股票代码：BMY）担任过多个高级管理职务。Nicaise博士拥有比利时布鲁塞尔大学的医学博士和内科、临床肿瘤学学位。
- Claude Nicaise has served on board of directors since March 16 2021. Dr. Nicaise is a physician with extensive US and international experience in clinical drug development, strategic management, worldwide regulatory strategy, pharmaceuticals, biotechnology, including clinical cancer research, infectious diseases and neuroscience. Dr. Nicaise is the owner and founder of Clinical Regulatory Services, which provides consulting services to the life science and biotechnology industry in support of all aspects of clinical and regulatory development. Dr. Nicaise currently serves on the board of directors and as the Chairman of the Compensation Committee of Sarepta Therapeutics, Inc. NASDAQ: SRPT, since 2015 as well as on the board of directors of Mynoryx Therapeutics, since 2017. Prior to that time, from 2008 to 2014 Dr. Nicaise served as the Senior Vice President of Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), and between 1984 and 2008 he held numerous senior management roles at Bristol Myers Squibb (NYSE: BMY). Dr. Nicaise holds an MD and a degree in Internal Medicine, Clinical Oncology, from Brussels University, Belgium.
- Douglas Ingram
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Deirdre P. Connelly
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Michael A. Chambers
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Stephen L. Mayo
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Kathryn Jean Boor
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- M. Kathleen Behrens
-
M. Kathleen Behrens自2019年1月起担任IGM Biosciences公司董事会成员。自2009年12月以来，Behrens博士一直担任独立生命科学顾问和投资者。2012年1月至2014年6月，她担任私营肿瘤服务公司KEW集团的联合创始人、总裁、首席执行官和董事。从1996年到2009年12月，Behrens博士在投资管理和研究公司RS Investments担任过各种职务，包括担任某些风险基金的普通合伙人。在此之前，从1983年至1996年，她担任Robertson Stephens & Co的普通合伙人和董事总经理。自2009年3月起，Behrens博士担任医学研究和药物开发公司Sarepta医疗的董事会成员，自2015年4月起担任董事长，并担任审计委员会主席和研究与开发委员会成员。2019年6月，她被选入伤口护理公司MiMedx Group的董事会，当时她被任命为董事长，并成为合规和伦理委员会的成员。Behrens博士从2009年6月开始担任生物制药公司Amylin Pharmaceuticals的董事会成员，直到2012年将其出售给Bristol-Myers Squibb。她曾于2001年至2009年初担任PCAST总统科技顾问委员会成员，并担任PCAST个性化医疗小组委员会主席。她还曾担任公共市场生物技术证券分析师和风险投资家，专注于医疗保健、技术和相关投资。她还曾担任国家研究委员会科学、技术和经济政策委员会成员，并担任国家风险投资协会主任、主席和主席。Behrens博士在University of California, Davis获得了生物科学学士学位和微生物学博士学位。
M. Kathleen Behrens has served as a member of IGM Biosciences, Inc.'s board of directors since January 2019. Since December 2009 Dr. Behrens has served as an independent life sciences consultant and investor. From January 2012 to June 2014 she served as the Co-Founder, President, Chief Executive Officer and director of the KEW Group, a private oncology services company. From 1996 to December 2009 Dr. Behrens served in various roles at RS Investments, an investment management and research firm, including as a General Partner for selected venture funds. Prior to this, from 1983 to 1996 she served as a General Partner and Managing Director at Robertson Stephens & Co. Since March 2009 Dr. Behrens has served as a member of the board of directors of Sarepta Therapeutics, a medical research and drug development company, and as Chairwoman since April 2015 as well as chair of its audit committee and a member of its research and development committee. She was elected to the board of MiMedx Group, a wound care company, in June, 2019 at which time she was named Chairwoman and became a member of the compliance and ethics committee. Dr. Behrens served on the board of directors of Amylin Pharmaceuticals, a biopharmaceutical company, from June 2009 until its sale to Bristol-Myers Squibb in 2012. She previously served as a member of the President's Council of Advisors on Science and Technology PCAST from 2001 to early 2009 and as Chairwoman of its subcommittee on Personalized Medicine. She has also spent time as a public-market biotechnology securities analyst and a venture capitalist focusing on healthcare, technology and related investments. She also previously served on the Board on Science, Technology and Economic Policy for the National Research Council and as a Director, President and Chairwoman of the National Venture Capital Association. Dr. Behrens received a B.S. in Biological Sciences and a Ph.D. in Microbiology from the University of California, Davis. - M. Kathleen Behrens自2019年1月起担任IGM Biosciences公司董事会成员。自2009年12月以来，Behrens博士一直担任独立生命科学顾问和投资者。2012年1月至2014年6月，她担任私营肿瘤服务公司KEW集团的联合创始人、总裁、首席执行官和董事。从1996年到2009年12月，Behrens博士在投资管理和研究公司RS Investments担任过各种职务，包括担任某些风险基金的普通合伙人。在此之前，从1983年至1996年，她担任Robertson Stephens & Co的普通合伙人和董事总经理。自2009年3月起，Behrens博士担任医学研究和药物开发公司Sarepta医疗的董事会成员，自2015年4月起担任董事长，并担任审计委员会主席和研究与开发委员会成员。2019年6月，她被选入伤口护理公司MiMedx Group的董事会，当时她被任命为董事长，并成为合规和伦理委员会的成员。Behrens博士从2009年6月开始担任生物制药公司Amylin Pharmaceuticals的董事会成员，直到2012年将其出售给Bristol-Myers Squibb。她曾于2001年至2009年初担任PCAST总统科技顾问委员会成员，并担任PCAST个性化医疗小组委员会主席。她还曾担任公共市场生物技术证券分析师和风险投资家，专注于医疗保健、技术和相关投资。她还曾担任国家研究委员会科学、技术和经济政策委员会成员，并担任国家风险投资协会主任、主席和主席。Behrens博士在University of California, Davis获得了生物科学学士学位和微生物学博士学位。
- M. Kathleen Behrens has served as a member of IGM Biosciences, Inc.'s board of directors since January 2019. Since December 2009 Dr. Behrens has served as an independent life sciences consultant and investor. From January 2012 to June 2014 she served as the Co-Founder, President, Chief Executive Officer and director of the KEW Group, a private oncology services company. From 1996 to December 2009 Dr. Behrens served in various roles at RS Investments, an investment management and research firm, including as a General Partner for selected venture funds. Prior to this, from 1983 to 1996 she served as a General Partner and Managing Director at Robertson Stephens & Co. Since March 2009 Dr. Behrens has served as a member of the board of directors of Sarepta Therapeutics, a medical research and drug development company, and as Chairwoman since April 2015 as well as chair of its audit committee and a member of its research and development committee. She was elected to the board of MiMedx Group, a wound care company, in June, 2019 at which time she was named Chairwoman and became a member of the compliance and ethics committee. Dr. Behrens served on the board of directors of Amylin Pharmaceuticals, a biopharmaceutical company, from June 2009 until its sale to Bristol-Myers Squibb in 2012. She previously served as a member of the President's Council of Advisors on Science and Technology PCAST from 2001 to early 2009 and as Chairwoman of its subcommittee on Personalized Medicine. She has also spent time as a public-market biotechnology securities analyst and a venture capitalist focusing on healthcare, technology and related investments. She also previously served on the Board on Science, Technology and Economic Policy for the National Research Council and as a Director, President and Chairwoman of the National Venture Capital Association. Dr. Behrens received a B.S. in Biological Sciences and a Ph.D. in Microbiology from the University of California, Davis.
- Hans Wigzell
-
Hans Wigzell，自2010年6月起担任董事会成员。他还担任提名和公司治理委员会成员，研究和开发委员会成员和主席。在过去的五年中，他曾担任Probi AB的董事，目前担任RaySearch Laboratories AB、Swedish Orphan Biovitrum AB和Valneva SE （Intercell AG的继任者）的董事。2006年以来，Wigzell博士担任Karolinska Development AB（一家在纳斯达克OMX斯德哥尔摩市场上市的公司，负责选择、开发和寻求将有前途的新北欧生命科学创新商业化的方法）的董事长。从1995年到2003年，他是Karolinska研究所（一所医科大学）的总裁；从1987年到1993年，他是斯德哥尔摩国家细菌学实验室的主任。Wigzell博士是斯德哥尔摩创业学院的董事会主席。他是几个国家科学院的当选成员，包括瑞典皇家工程学院，瑞典；瑞典皇家科学院；丹麦艺术与文学学院；美国艺术与科学院；芬兰科学学会；以及欧洲分子生物学组织。除了担任卡罗林斯卡学院院长外，他的学术生涯还包括担任诺贝尔奖委员会主席、卡罗林斯卡学院主席和日本爱媛大学杰出外部顾问教授。此外，Wigzell博士于2000年被任命为诺贝尔大会主席。他拥有斯德哥尔摩卡罗林斯卡研究所的医学博士和博士学位，并在意大利罗马的“Tor Vergata”大学、芬兰的图尔库大学和纽约的Feinstein研究所获得荣誉博士学位。
Hans Wigzell, has served as a member of Board since June 2010. He also serves as a member of nominating and corporate governance committee and a member of and chairperson of research and development committee. In the past five years, Dr. Wigzell has served as a director of Probi AB and currently serves as a director of RaySearch Laboratories AB, Swedish Orphan Biovitrum AB, and Valneva SE a successor to Intercell AG. Since 2006 Dr. Wigzell has served as Chairman of Karolinska Development AB, a company listed on the NASDAQ OMX Stockholm market that selects, develops and seeks ways to commercialize promising new Nordic lifescience innovations. From 1995 to 2003 he was the President of the Karolinska Institute, a medical university and was General Director of the National Bacteriological Laboratory in Stockholm from 1987 to 1993. Dr. Wigzell is Chairman of the board of the Stockholm School of Entrepreneurship. He is an elected member of several national academies, including the Swedish Royal Engineering Academy, Sweden; the Royal Academy of Science, Sweden; the Danish Academy of Arts and Letters; the American Academy of Arts and Sciences; the Finnish Science Society; and the European Molecular Biology Organization. In addition to serving as President of the Karolinska Institute, his academic career includes being Chairman of the Nobel Prize Committee, and the Karolinska Institute and Distinguished External Advisory Professor of Ehime University, Japan. Additionally, Dr. Wigzell was appointed Chairman of the Nobel Assembly in 2000. Dr. Wigzell holds an M.D. and Ph.D. from the Karolinska Institute in Stockholm and he has received honorary doctorate degrees at University "Tor Vergata" in Rome, Italy, Turku University in Finland and The Feinstein Institute in New York. - Hans Wigzell，自2010年6月起担任董事会成员。他还担任提名和公司治理委员会成员，研究和开发委员会成员和主席。在过去的五年中，他曾担任Probi AB的董事，目前担任RaySearch Laboratories AB、Swedish Orphan Biovitrum AB和Valneva SE （Intercell AG的继任者）的董事。2006年以来，Wigzell博士担任Karolinska Development AB（一家在纳斯达克OMX斯德哥尔摩市场上市的公司，负责选择、开发和寻求将有前途的新北欧生命科学创新商业化的方法）的董事长。从1995年到2003年，他是Karolinska研究所（一所医科大学）的总裁；从1987年到1993年，他是斯德哥尔摩国家细菌学实验室的主任。Wigzell博士是斯德哥尔摩创业学院的董事会主席。他是几个国家科学院的当选成员，包括瑞典皇家工程学院，瑞典；瑞典皇家科学院；丹麦艺术与文学学院；美国艺术与科学院；芬兰科学学会；以及欧洲分子生物学组织。除了担任卡罗林斯卡学院院长外，他的学术生涯还包括担任诺贝尔奖委员会主席、卡罗林斯卡学院主席和日本爱媛大学杰出外部顾问教授。此外，Wigzell博士于2000年被任命为诺贝尔大会主席。他拥有斯德哥尔摩卡罗林斯卡研究所的医学博士和博士学位，并在意大利罗马的“Tor Vergata”大学、芬兰的图尔库大学和纽约的Feinstein研究所获得荣誉博士学位。
- Hans Wigzell, has served as a member of Board since June 2010. He also serves as a member of nominating and corporate governance committee and a member of and chairperson of research and development committee. In the past five years, Dr. Wigzell has served as a director of Probi AB and currently serves as a director of RaySearch Laboratories AB, Swedish Orphan Biovitrum AB, and Valneva SE a successor to Intercell AG. Since 2006 Dr. Wigzell has served as Chairman of Karolinska Development AB, a company listed on the NASDAQ OMX Stockholm market that selects, develops and seeks ways to commercialize promising new Nordic lifescience innovations. From 1995 to 2003 he was the President of the Karolinska Institute, a medical university and was General Director of the National Bacteriological Laboratory in Stockholm from 1987 to 1993. Dr. Wigzell is Chairman of the board of the Stockholm School of Entrepreneurship. He is an elected member of several national academies, including the Swedish Royal Engineering Academy, Sweden; the Royal Academy of Science, Sweden; the Danish Academy of Arts and Letters; the American Academy of Arts and Sciences; the Finnish Science Society; and the European Molecular Biology Organization. In addition to serving as President of the Karolinska Institute, his academic career includes being Chairman of the Nobel Prize Committee, and the Karolinska Institute and Distinguished External Advisory Professor of Ehime University, Japan. Additionally, Dr. Wigzell was appointed Chairman of the Nobel Assembly in 2000. Dr. Wigzell holds an M.D. and Ph.D. from the Karolinska Institute in Stockholm and he has received honorary doctorate degrees at University "Tor Vergata" in Rome, Italy, Turku University in Finland and The Feinstein Institute in New York.
高管简历
中英对照 | 中文 | 英文- Ian Estepan
Ian Estepan，自2020年12月起担任公司执行副总裁、首席财务官。Estepan先生于2015年1月加入公司，担任公司事务高级总监。2016年10月至2017年12月，任公司事务执行董事；2018年1月至2019年2月，任副总裁、参谋长及公司事务；2019年2月至2020年12月，任高级副总裁、参谋长及公司事务。自2021年11月以来，Estepan先生一直担任民营生物制药公司Celarity的董事会成员。Estepan先生目前担任私营生物制药公司ABBC Therapies的执行董事长。在加入公司之前，Estepan先生在Spectra Financial Group的买方管理投资组合长达15年，负责监管制药、生物技术和医疗技术股票的投资组合。Estepan先生获得了哥伦比亚大学主修预科医学的心理学文学学士学位。
Ian Estepan,has served as the Company's Executive Vice President, Chief Financial Officer since December 2020. Mr. Estepan joined the Company in January 2015 as Senior Director, Corporate Affairs. From October 2016 to December 2017, he served as Executive Director, Corporate Affairs; from January 2018 to February 2019, he served as Vice President, Chief of Staff and Corporate Affairs; and from February 2019 to December 2020, he served as Senior Vice President, Chief of Staff and Corporate Affairs. Since November 2021, Mr. Estepan has served on the Board of Directors for Cellarity, a private biopharmaceutical company. Mr. Estepan currently serves as Executive Chairman of AbBC Therapies, a private biopharmaceutical company. Prior to joining the Company, Mr. Estepan managed a portfolio on the buyside at Spectra Financial Group for 15 years, overseeing a portfolio of pharmaceutical, biotech and medtech equities. Mr. Estepan received his Bachelor of Arts in psychology with a concentration in pre-medicine from Columbia University.- Ian Estepan，自2020年12月起担任公司执行副总裁、首席财务官。Estepan先生于2015年1月加入公司，担任公司事务高级总监。2016年10月至2017年12月，任公司事务执行董事；2018年1月至2019年2月，任副总裁、参谋长及公司事务；2019年2月至2020年12月，任高级副总裁、参谋长及公司事务。自2021年11月以来，Estepan先生一直担任民营生物制药公司Celarity的董事会成员。Estepan先生目前担任私营生物制药公司ABBC Therapies的执行董事长。在加入公司之前，Estepan先生在Spectra Financial Group的买方管理投资组合长达15年，负责监管制药、生物技术和医疗技术股票的投资组合。Estepan先生获得了哥伦比亚大学主修预科医学的心理学文学学士学位。
- Ian Estepan,has served as the Company's Executive Vice President, Chief Financial Officer since December 2020. Mr. Estepan joined the Company in January 2015 as Senior Director, Corporate Affairs. From October 2016 to December 2017, he served as Executive Director, Corporate Affairs; from January 2018 to February 2019, he served as Vice President, Chief of Staff and Corporate Affairs; and from February 2019 to December 2020, he served as Senior Vice President, Chief of Staff and Corporate Affairs. Since November 2021, Mr. Estepan has served on the Board of Directors for Cellarity, a private biopharmaceutical company. Mr. Estepan currently serves as Executive Chairman of AbBC Therapies, a private biopharmaceutical company. Prior to joining the Company, Mr. Estepan managed a portfolio on the buyside at Spectra Financial Group for 15 years, overseeing a portfolio of pharmaceutical, biotech and medtech equities. Mr. Estepan received his Bachelor of Arts in psychology with a concentration in pre-medicine from Columbia University.
- Louise Rodino Klapac
Louise Rodino Klapac，自2020年12月起担任公司执行副总裁、首席科学官。Rodino-Klapac博士于2021年11月被额外任命为Sarepta Therapeutics, Inc.研发主管。Rodino-Klapac博士于2018年4月加入公司，担任基因治疗副总裁。2019年2月至2020年12月，担任Sarepta Therapeutics, Inc.基因治疗高级副总裁。在加入公司之前，她曾担任全国儿童医院基因治疗研究实验室的负责人，并在Myonexus Therapeutics于2019年被公司收购之前共同创立并担任首席科学官。她是美国国立卫生研究院（National Institutes of Health，简称NIH）的研究员任命，是再生医学协会现任董事会成员，也是美国基因和细胞治疗学会、美国神经病学学会的成员。她拥有金斯学院生物学理学学士学位和俄亥俄州立大学分子遗传学博士学位。
Louise Rodino Klapac,has served as the Company's Executive Vice President, Chief Scientific Officer since December 2020. Dr. Rodino-Klapac was additionally appointed as Sarepta Therapeutics, Inc. Head of R&D in November 2021. Dr. Rodino-Klapac joined the Company as Vice President, Gene Therapy in April 2018. From February 2019 to December 2020, she served as Sarepta Therapeutics, Inc. Senior Vice President, Gene Therapy. Prior to joining the Company, she served as the head of the Laboratory for Gene Therapy Research at Nationwide Children's Hospital and co-founded and served as chief scientific officer of Myonexus Therapeutics before it was acquired by the Company in 2019. She is a National Institutes of Health (NIH) Fellow appointee and is a current board member of the Association for Regenerative Medicine, as well as a member of the American Society for Gene and Cell Therapy, and the American Academy of Neurology. She holds a Bachelor of Science degree in biology from Kings College and a Ph.D. in molecular genetics from Ohio State University.- Louise Rodino Klapac，自2020年12月起担任公司执行副总裁、首席科学官。Rodino-Klapac博士于2021年11月被额外任命为Sarepta Therapeutics, Inc.研发主管。Rodino-Klapac博士于2018年4月加入公司，担任基因治疗副总裁。2019年2月至2020年12月，担任Sarepta Therapeutics, Inc.基因治疗高级副总裁。在加入公司之前，她曾担任全国儿童医院基因治疗研究实验室的负责人，并在Myonexus Therapeutics于2019年被公司收购之前共同创立并担任首席科学官。她是美国国立卫生研究院（National Institutes of Health，简称NIH）的研究员任命，是再生医学协会现任董事会成员，也是美国基因和细胞治疗学会、美国神经病学学会的成员。她拥有金斯学院生物学理学学士学位和俄亥俄州立大学分子遗传学博士学位。
- Louise Rodino Klapac,has served as the Company's Executive Vice President, Chief Scientific Officer since December 2020. Dr. Rodino-Klapac was additionally appointed as Sarepta Therapeutics, Inc. Head of R&D in November 2021. Dr. Rodino-Klapac joined the Company as Vice President, Gene Therapy in April 2018. From February 2019 to December 2020, she served as Sarepta Therapeutics, Inc. Senior Vice President, Gene Therapy. Prior to joining the Company, she served as the head of the Laboratory for Gene Therapy Research at Nationwide Children's Hospital and co-founded and served as chief scientific officer of Myonexus Therapeutics before it was acquired by the Company in 2019. She is a National Institutes of Health (NIH) Fellow appointee and is a current board member of the Association for Regenerative Medicine, as well as a member of the American Society for Gene and Cell Therapy, and the American Academy of Neurology. She holds a Bachelor of Science degree in biology from Kings College and a Ph.D. in molecular genetics from Ohio State University.
- Ryan Wong
Ryan Wong，自2025年3月起担任公司高级副总裁，负责战略财务、财务和投资者关系。2022年3月至2025年3月，任财务战略、规划分析和财务副总裁。黄先生于2021年7月加入公司，担任财务战略、规划与分析副总裁。2017年6月至2021年7月，Wong先生曾任职于GW Pharmaceuticals PLC，最近担任财务副总裁。他拥有加州大学欧文分校中国语言文学文学学士学位和南加州大学马歇尔商学院会计学硕士学位。
Ryan Wong,has served as the Company's Senior Vice President, Strategic Finance, Treasury and Investor Relations since March 2025. From March 2022 to March 2025, he served as Vice President, Financial Strategy, Planning & Analysis and Treasury. Mr. Wong joined the Company as Vice President, Financial Strategy, Planning & Analysis in July 2021. From June 2017 to July 2021, Mr. Wong worked at GW Pharmaceuticals plc, most recently as Vice President, Finance. He holds a Bachelor of Arts degree in Chinese language and literature from University of California Irvine and a Master's degree in accounting from the University of Southern California Marshall School of Business.- Ryan Wong，自2025年3月起担任公司高级副总裁，负责战略财务、财务和投资者关系。2022年3月至2025年3月，任财务战略、规划分析和财务副总裁。黄先生于2021年7月加入公司，担任财务战略、规划与分析副总裁。2017年6月至2021年7月，Wong先生曾任职于GW Pharmaceuticals PLC，最近担任财务副总裁。他拥有加州大学欧文分校中国语言文学文学学士学位和南加州大学马歇尔商学院会计学硕士学位。
- Ryan Wong,has served as the Company's Senior Vice President, Strategic Finance, Treasury and Investor Relations since March 2025. From March 2022 to March 2025, he served as Vice President, Financial Strategy, Planning & Analysis and Treasury. Mr. Wong joined the Company as Vice President, Financial Strategy, Planning & Analysis in July 2021. From June 2017 to July 2021, Mr. Wong worked at GW Pharmaceuticals plc, most recently as Vice President, Finance. He holds a Bachelor of Arts degree in Chinese language and literature from University of California Irvine and a Master's degree in accounting from the University of Southern California Marshall School of Business.
- Douglas Ingram
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Cristin Rothfuss
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介